EGFR and non-small cell lung carcinoma: Like tyrosine kinase inhibitors (TKIs) for epidermal growth factor receptor (EGFR), a classical and effective therapeutic target for NSCLC therapy, although the drugs erlotinib and gefitinib are very effective in treating NSCLC, they indeed cause side effects such as rash and diarrhea (208).